NewLink Genetics Corp. has entered into a clinical collaboration agreement with global drugmaker AstraZeneca to evaluate a combination of one of its cancer drugs with an AstraZeneca drug. The Phase 2 study will evaluate combining indoximod, NewLink Genetics' small molecule IDO pathway inhibitor, and durvalumab, AstraZeneca's anti-PD-L1 monoclonal antibody, along with standard-of-care chemotherapy for patients with metastatic pancreatic cancer. The trial will be funded equally by both companies, with NewLink Genetics serving as the study sponsor. Recent data have indicated that indoximod combinations with immunotherapy and chemotherapy show promise of improving outcomes for patients with multiple tumor types, said Dr. Charles Link Jr., chairman, CEO and chief scientific officer of NewLink, which is based in Ames.